PHILADELPHIA, Aug. 04, 2026 (GLOBE NEWSWIRE) —
Erasca, Inc. (NASDAQ: ERAS):
Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed to the Company and its shareholders.
What is This Investigation About? The investigation concerns whether Erasca’s directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company’s public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.
If you are a current Erasca (NASDAQ: ERAS) shareholder who has held shares since prior to January 14, 2025, you seek corporate governance reforms, damages on behalf of the Company, and a court approved incentive award at no cost to you whatsoever. Please visit
https://grabarlaw.com/the-latest/erasca-shareholder-investigation/
,
contact Joshua H. Grabar at
[email protected]
, or call us at 267-507-6085.
What is Alleged? According to a recently filed federal securities class action, investors allege that Erasca made materially misleading statements and omissions concerning ERAS-0015. Among other things, the complaint alleges that: Erasca publicly promoted ERAS-0015 as a potential “best-in-class” therapy and made repeated comparisons between ERAS-0015 and Revolution Medicines’ RMC-6236; the Company’s public disclosures allegedly relied upon improper comparisons to RMC-6236; Erasca allegedly faced intellectual property, patent, and trade-secret-related risks associated with those comparisons and related disclosures; investors allegedly were not adequately informed of those risks; and certain positive statements regarding ERAS-0015 allegedly lacked a reasonable basis.
April 2026 Disclosures: On April 27, 2026, Erasca disclosed that it had received correspondence from counsel for Revolution Medicines alleging, among other things, patent infringement, trade-secret-related issues, and allegedly improper comparative statements concerning ERAS-0015 and RMC-6236. Later that same day, Erasca disclosed preliminary Phase 1 clinical data regarding ERAS-0015 and reported that one patient who received ERAS-0015 had died after experiencing pneumonitis that progressed following withdrawal of supportive care. The Company also disclosed that comparisons between ERAS-0015 and other product candidates were based on cross-study analyses rather than head-to-head clinical trials and that such comparisons were inherently limited. Following these disclosures, Erasca’s share price experienced a substantial decline.
What Can You Do Now?
If you are a current Erasca (NASDAQ: ERAS) shareholder and have held shares since prior to January 14, 2025, you can seek corporate governance reforms, damages on behalf of the Company, and a court approved incentive award at no cost to you whatsoever. Please visit
https://grabarlaw.com/the-latest/erasca-shareholder-investigation/
,
contact Joshua H. Grabar at
[email protected]
, or call us at 267-507-6085. #Erasca #ERAS $ERAS
Insulet Corporation (NASDAQ: PODD):
Grabar Law Office is investigating claims on behalf of shareholders of Insulet Corporation (NASDAQ: PODD).
What Is This Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
If you purchased
Insulet Corporation (NASDAQ: PODD)
shares prior to February 21, 2025
,
and still hold shares today,
you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.
Please visit
https://grabarlaw.com/the-latest/insulet-shareholder-investigation/
, contact Joshua Grabar at
[email protected]
,
or call 267-507-6085.
What Is Alleged? As alleged in a recently filed federal securities fraud class action complaint, Insulet Corporation (NASDAQ: PODD), through certain of its executives, violated federal securities laws by making false and/or misleading statements and/or failed to disclose that: (i) Insulet’s manufacturing controls and procedures were defective; (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (iii) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
The truth began to emerge on March 12, 2026, when Insulet disclosed that it had “initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue through its ongoing product monitoring.” Then, on May 26, 2026, Insulet disclosed the “initat[ion]” of another “voluntary Medical Device Correction” (the “May 2026 MDC”), this time “for specific lots of Omnipod® 5, Omnipod Dash®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery.”
What Can You Do Now?
If you purchased
Insulet Corporation (NASDAQ: PODD)
shares prior to February 21, 2025
,
and still hold shares today,
you are encouraged to visit
https://grabarlaw.com/the-latest/insulet-shareholder-investigation/
, contact Joshua Grabar at
[email protected]
,
or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. #Insulet, #PODD $PODD
Power Solutions International, Inc. (NASDAQ: PSIX)
:
Grabar Law Office is investigating claims on behalf of shareholders of Power Solutions International, Inc. (NASDAQ: PSIX).
What Is This Investigation About? The investigation concerns whether Power Solutions and certain of its executives breached their fiduciary duties.
If you purchased
Power Solutions International, Inc. (NASDAQ: PSIX) shares prior to May 8, 2025, please
visit
https://grabarlaw.com/the-latest/psix-shareholder-investigation/
, contact Joshua H. Grabar at [email protected], or call 267-507-6085. You can seek corporate reforms, the return of funds back to the Company, and a court approved incentive award at no cost you whatsoever.
What is Alleged? According to a recently filed federal securities fraud class action complaint, Power Solutions (NASDAQ: PSIX); through certain of its officers, failed to disclose to investors: (1) the Company overstated its ability to capture sales demand for its power systems solutions, particularly within the data center market; (2) the Company understated the impact of its enhancements to manufacturing capacity to meet demand within the data center market, including the expected costs and the nature of the related “inefficiencies”; and (3) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
What Can You Do Now?
If you purchased or otherwise acquired
Power Solutions International, Inc. (NASDAQ: PSIX) securities prior to May 8, 2025,
you can
seek corporate reforms, the return of funds back to the Company, and a court approved incentive award at no cost you whatsoever. Visit https://grabarlaw.com/the-latest/psix-shareholder-investigation/, contact Joshua H. Grabar at [email protected], or call 267-507-6085 to learn more. #PSIX $PSIX #PowerSolutions
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
:
Grabar Law Office is investigating claims on behalf of shareholders of PROCEPT BioRobotics Corporation (NASDAQ: PRCT).
What is This Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
If you purchased
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
shares before
February 28, 2024
, and still hold shares today,
you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit
https://grabarlaw.com/the-latest/procept-shareholder-investigation/
, contact Joshua Grabar at
[email protected]
,
or call 267-507-6085.
What is Alleged? As alleged in a recently filed securities fraud class action PROCEPT BioRobotics Corporation (NASDAQ: PRCT), through certain of its officers, made materially false and misleading statements and/or failed to disclose materially adverse facts including: (i) that Procept had utilized an extensive discount program designed to incentivize its customers to place bulk orders in excess of procedure demand; (ii) that Procept’s undisclosed discount program had artificially and unsustainably inflated Procept’s reported U.S. handpiece unit sales and revenues by pulling forward sales at the expense of future periods; (iii) that Procept’s undisclosed discount program had caused customer handpiece orders to materially exceed underlying procedure demand throughout the Class Period and that this differential had materially grown over time; (iv) that Procept’s consistent surplus of U.S. handpiece unit sales relative to performed procedures had created a glut of field inventory and overstocking amongst Procept’s customer base, amounting to more than 10,000 excess units by the end of the Class Period; (v) that, as a result of (i)-(iv) above, defendants’ representations regarding Procept’s handpiece unit sales and the utilization of Procept’s field Systems were materially overstated; (vi) that, as a result of (i)-(v) above, Procept was acutely exposed to material undisclosed risks of significant operational and financial harm; and (vii) that, as a result of (i)-(vi) above, Procept was unable to achieve its stated 2025 handpiece sales and revenue guidance and such guidance lacked a reasonably achievable factual basis.
What Can You Do Now?
If you purchased
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
shares before
February 28, 2024
, and still hold shares today,
you are encouraged to visit
https://grabarlaw.com/the-latest/procept-shareholder-investigation/
, contact Joshua Grabar at
[email protected]
,
or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. #Procept #PRCT $PRCT
Attorney Advertising Disclaimer
Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: [email protected]
